Faculty Collaboration Database

1. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Jun 08;388(23):2159-2170. PMCID: PMC10351614

2. Barber EL, Chen S, Pineda MJ, Robertson SE, Hill EK, Teoh D, Schilder J, O'Shea KL, Kocherginsky M, Zhang B, Matei D. Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. Cancer Res Commun. 2022 Oct;2(10):1293-1303. PMCID: PMC9648489

3. Mattson J, Emerson J, Underwood A, Sun G, Mott SL, Kulkarni A, Robison K, Hill EK. Superficial versus deep inguinal nodal dissection for vulvar cancer staging. Gynecol Oncol. 2022 Sep;166(3):465-470.

4. Faidley KN, Botkin HE, Loeffler BT, Mott SL, Hansen SC, Hill EK, Erickson BA. Longitudinal Outcomes of Malignant Ureteral Obstruction Secondary to Ovarian Cancer: Predictors of Resolution and the Role of Surgical Management. Urology. 2024 Apr;186:101-106. PMCID: PMC11816973

5. Metzger S, Ulmer K, Hill EK. Pembrolizumab-induced cytokine release syndrome with severe encephalopathy in the setting of clear cell vaginal carcinoma: A case report. Gynecol Oncol Rep. 2024 Dec;56:101529. PMCID: PMC11530849

6. Gorzelitz J, Adeagbo M, Dungan-Seaver S, Hill EK, Kumar A, Goodheart MJ, Lutgendorf S. Attitudes, beliefs and preferences surrounding home-based exercise programs in endometrial cancer patients receiving treatment. Gynecol Oncol Rep. 2025 Feb;57:101659. PMCID: PMC11730264

7. Rocque GB, Dent DN, Waugh C, Hill EK, Federman N, Bostock Rosenzweig I, Morris B, Kamal A. Evaluating the implementation and impact of a volunteer navigation oncology support programme: study protocol for a pragmatic, real-world hybrid type 2 study. BMJ Open. 2025 Jan 20;15(1):e088047. PMCID: PMC11748934

8. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med. 2025 May;31(5):1539-1546. PMCID: PMC12851417

9. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer Obstetrical and Gynecological Survey. 1 July 2023;78(7):406-407.

10. Botkin HE, Faidley KN, Loeffler BT, Mott SL, Hill EK, Erickson BA. Longitudinal Outcomes from Conservative Management of Cervical Cancer Associated Ureteral Obstruction. Urology. 2021 Dec;158:208-214.

11. Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. PMCID: PMC8127359

12. Teoh D, Hill EK, Goldsberry W, Levine L, Novetsky A, Downs L Jr. Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.: A Society of Gynecologic Oncology (SGO) Review. Gynecol Oncol. 2021 Apr;161(1):228-235.

13. Mattson J, Thayer M, Mott SL, Lyons YA, Hardy-Fairbanks A, Hill EK. Multimodal perioperative pain protocol for gynecologic laparotomy is associated with reduced hospital length of stay. J Obstet Gynaecol Res. 2021 Mar;47(3):1082-1089.

14. Gnade CM, Hill EK, Botkin HE, Hefel AR, Hansen HE, Sheets KA, Mott SL, Hardy-Fairbanks AJ, Stockdale CK. Is the age of cervical cancer diagnosis changing over time? J Gynecol Obstet Hum Reprod. 2021 Sep;50(7):102040.

15. Gnade CM, Hill EK, Botkin HE, Hefel AR, Hansen HE, Sheets KA, Mott SL, Hardy-Fairbanks AJ, Stockdale CK. Effect of Obesity on Cervical Cancer Screening and Outcomes. J Low Genit Tract Dis. 2020 Oct;24(4):358-362.

16. Hill EK. Updates in Cervical Cancer Treatment. Clin Obstet Gynecol. 2020 Mar;63(1):3-11.

17. Hill EK, Stuckey A, Fiascone S, Raker C, Clark MA, Brown A, Gordinier M, Robison K. Gender and the Balance of Parenting and Professional Life among Gynecology Subspecialists. J Minim Invasive Gynecol. 2019;26(6):1088-1094.

18. McDonald ME, Mattson J, Hill E. Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer Gynecologic Oncology Reports. 1 May 2017;20:103-104.

19. Cass I, Duska LR, Blank SV, Cheng G, Dupont NC, Frederick PJ, Hill EK, Matthews CM, Pua TL, Rath KS, Ruskin R, Thaker PH, Berchuck A, Gostout BS, Kushner DM, Fowler JM. Stress and burnout among gynecologic oncologists: A society of gynecologic oncology evidence-based review and recommendations Obstetrical and Gynecological Survey. 1 December 2016;71(12):715-717.

20. Cass I, Duska LR, Blank SV, Cheng G, duPont NC, Frederick PJ, Hill EK, Matthews CM, Pua TL, Rath KS, Ruskin R, Thaker PH, Berchuck A, Gostout BS, Kushner DM, Fowler JM. Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations. Gynecol Oncol. 2016 Nov;143(2):421-427.

21. Hill EK, Blake RA, Emerson JB, Svider P, Eloy JA, Raker C, Robison K, Stuckey A. Gender Differences in Scholarly Productivity Within Academic Gynecologic Oncology Departments. Obstet Gynecol. 2015 Dec;126(6):1279-1284. PMCID: PMC4868082

22. Guthrie ML, Sidhu PS, Hill EK, Horan TC, Nandhikonda P, Teske KA, Yuan NY, Sidorko M, Rodali R, Cook JM, Han L, Silvaggi NR, Bikle DD, Moore RG, Singh RK, Arnold LA. Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. Anticancer Res. 2015 Nov;35(11):6001-7. PMCID: PMC4633305

23. Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. Sci Rep. 2014 Jan 06;4:3574. PMCID: PMC3880958

24. Hill EK, Dizon DS. Medical therapy of endometrial cancer: current status and promising novel treatments. Drugs. 2012 Mar 26;72(5):705-13.

25. Barlin JN, Yu C, Hill EK, Zivanovic O, Kolev V, Levine DA, Sonoda Y, Abu-Rustum NR, Huh J, Barakat RR, Kattan MW, Chi DS. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2012 Apr;125(1):25-30.

26. Hill EK, Sandbo S, Abramsohn E, Makelarski J, Wroblewski K, Wenrich ER, McCoy S, Temkin SM, Yamada SD, Lindau ST. Assessing gynecologic and breast cancer survivors' sexual health care needs. Cancer. 2011 Jun 15;117(12):2643-51. PMCID: PMC3084902

27. Dale W, Hemmerich J, Hill EK, Hougham GW, Sachs GA. What correlates with the intention to be tested for mild cognitive impairment (MCI) in healthy older adults? Alzheimer Dis Assoc Disord. 2008;22(2):144-52.

28. Dale W, Hougham GW, Hill EK, Sachs GA. High interest in screening and treatment for mild cognitive impairment in older adults: A pilot study. J Am Geriatr Soc. 2006 Sep;54(9):1388-94.